Diagnosis of Myocardial Ischemia With MCG Using SPECT as a Reference Standard

Last updated: August 19, 2024
Sponsor: Qilu Hospital of Shandong University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Thrombosis

Myocardial Ischemia

Vascular Diseases

Treatment

Magnetocardiography

Single photon emission computed tomography (SPECT)

Clinical Study ID

NCT06255769
MCG-SPECT
  • Ages > 18
  • All Genders

Study Summary

This is a prospective clinical study aiming to investigate the efficacy of Magnetocardiography (MCG) in detecting myocardial ischemia in patients of a suspected non-ST-elevation-acute coronary syndrome (NSTE-ACS) by using Single photon emission computed tomography (SPECT) as the gold standard for determining the presence and severity of myocardial ischemia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18 years or older;

  • Patients with symptoms of myocardial ischemia such as angina pectoris, who have CAGshowing <70% stenosis at the most severe site or CTA showing non-severe stenosis

  • Signed informed consent.

Exclusion

Exclusion Criteria:

  • Patients with absolute or relative contraindications to SPECT-loaded myocardialperfusion, including acute myocardial infarction within 48 hours, significant leftmain coronary artery stenosis, bronchial asthma, and adenosine injection allergy;

  • Patients with Non-ischemic dilated cardiomyopathy, or hypertrophic cardiomyopathy,or moderate or severe valvular disease;

  • Patients with Hemodynamic instability (systolic blood pressure<90 mmHg, or whorequires vasoactive drugs), or patients with tachyarrhythmia, Ⅱdegreeatrioventricular block and above that have not returned to normal;

  • Patients who have severe renal abnormality with eGFR <30 ml/min, or patients who areon dialysis;

  • Patients with malignant tumors with predicted survival of less than 1 year;

  • Pregnant or breastfeeding women;

  • Patients who are unable to enter the MCG device, who are unable to perform MCGexamination due to interference from metal implants or other reasons, or who aredeemed by the investigators to be unsuitable for enrollment.

Study Design

Total Participants: 228
Treatment Group(s): 2
Primary Treatment: Magnetocardiography
Phase:
Study Start date:
February 12, 2024
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Qilu Hospital of Shandong University

    Jinan, Shandong 250012
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.